Flash Chemiluminescence Assays on the KleeYa® Platform
Combine the sensitivity and accuracy of ALPCO flash chemiluminescence assays with the efficiency of the KleeYa platform to streamline analysis for the tests that matter most.
KleeYa Platform
The KleeYa platform is a fully automated random-access analyzer that provides fast and flexible biomarker testing, streamlining workflows and simplifying menu expansion.
Sample-to-Answer: Walk-away testing with continuous loading of samples, reagents, and consumables
Random Access: Up to 16 on-board assays with on-demand results in ~30 minutes
Medium Throughput: Up to 120 tests per hour
User-Friendly Workflow: Intuitive interface indicating resource and testing status
Advances in diagnostic testing continue to reshape how gastrointestinal diseases are studied, detected, and monitored. Explore our resources to learn more about biomarkers, testing strategies, and emerging insights in GI health.
Syphilis testing has become increasingly complex, with traditional and reverse testing algorithms, testing of pregnant women and high-risk patients, and multiple factors (biological false positives, past syphillis infection, DOXYpep treatment, etc.) affecting clinical decision-making. Explore our resources to learn more about our solutions for syphillis testing.
Studies have demonstrated that drug level testing and anti-drug antibody testing are critical components in the successful treatment of inflammatory disease. Explore our resources to learn more about therapeutic drug monitoring.
The Vedolizumab Total Anti-Drug Antibody CLIA Kit is a chemiluminescent immunoassay for the semi-quantitative determination of total antibodies to vedolizumab (therapeutic antibody against α4β7 integrin) using the KleeYa platform.
The Ustekinumab Total Anti-Drug Antibody CLIA Kit is a chemiluminescent immunoassay for the semi-quantitative determination of total antibodies to ustekinumab (therapeutic antibody against the p40 subunit of IL-12 and IL-23) using the KleeYa platform.
The Infliximab Total Anti-Drug Antibody CLIA Kit is a chemiluminescent immunoassay for the semi-quantitative determination of total antibodies to infliximab (therapeutic antibody against TNFα) using the KleeYa platform.
The Adalimumab Total Anti-Drug Antibody CLIA Kit is a chemiluminescent immunoassay for the semi-quantitative determination of total antibodies to adalimumab (therapeutic antibody against TNFα) using the KleeYa platform
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
Gastroenterology
Our automated testing solutions provide insights into the digestive system with a growing menu of gastroenterology assays for molecular diagnostics and immunodiagnostics. Get insights for a variety of diseases that affect the intestinal tract.
D
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor
1. What percentage of your IgE allergy testing panel consists of molecular allergens rather than allergen extracts? The ALEX2 IgE allergen panel consists of 117 extracts and 183 molecular allergens. This represents the largest panel of molecular allergens on the market, including 50 unique...
Cases of food and environmental allergies have been increasing over the last decade. While conservative estimates suggest IgE-mediated allergy affects 6-8% of children and 2-3% of adults, some estimates are as high as 30%.3, 2 Symptoms can range from mild to severe and include itching, hives,...
Food sensitivity or food intolerance involves a non-allergic response to a food or food additive. In a recent on-line survey conducted in the U.S., 24% of adults aged 18 to 79 reported a food intolerance. While a food allergy is typically mediated by IgE antibodies, adverse reactions to food...
In a head-to-head comparison of FDA-cleared assays and a novel ALPCO method, investigators observed wide variability in specificity and false-positive rates across platforms, raising important questions about standardization and clinical interpretation.
July 22, 2025 – Salem, NH – NuvinkaDx, a leading innovator in diagnostic solutions, today announced two significant product and regulatory milestones from its operating companies, GeneProof and ALPCO.
Energy homeostasis is a focus of research into diabetes and obesity. Read about how our assays in this area can assist both academic and industry researchers.
Complement System Solutions for Drug Development and Clinical Research Datasheet
The complement system is essential to innate immunity from a variety of diseases. ALPCO’s full range of complement system immunoassays can drive discovery.
Melatonin Products for Sleep Disorder-Related Research Datasheet
The melatonin hormone affects the circadian rhythm and sleep-wake cycle. Find out about our immunoassays and products that explore melatonin and sleep disorders.